Safety of the Polish BCG-10 Vaccine during a Period of BCG Vaccine Shortage: An Australian Experience

Nicole X. Wong; Jim Buttery; Alissa McMinn; Zainul Azhar; Nigel W. Crawford

doi:10.1097/INF.0000000000002630

Safety of the Polish BCG-10 Vaccine during a Period of BCG Vaccine Shortage: An Australian Experience

Nicole X. Wong
, Jim Buttery
, Alissa McMinn
, Zainul Azhar
, Nigel W. Crawford

Paediatrics Monash Health

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

Abstract

Bacille Calmete-Guerin vaccine is widely administered to reduce the risk of severe tuberculosis disease in children. Recent global vaccine supply issues have led to the use of alternative products, which may vary in side effect profile. We report on the safety of the Polish (Moreau strain) "Bacille Calmete-Guerin-10" vaccine in an Australian cohort. Using active surveillance, we identified an adverse event rate of 54.6 per 10,000 doses (95% confidence interval: 38.5-75.2), which was comparable to that reported with the Danish Sanofi-Pasteur and Connaught strains.

Original language	English
Pages (from-to)	E66-E68
Number of pages	3
Journal	The Pediatric Infectious Disease Journal
Volume	39
Issue number	6
DOIs	https://doi.org/10.1097/INF.0000000000002630
Publication status	Published - Jun 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

adverse events following immunization
Bacille Calmete-Guerin
vaccine safety

Access to Document

10.1097/INF.0000000000002630

315618801-oaFinal published version, 302 KB

Cite this

@article{a603499972e24e948aa4b283f7e3b46b,

title = "Safety of the Polish BCG-10 Vaccine during a Period of BCG Vaccine Shortage: An Australian Experience",

abstract = "Bacille Calmete-Guerin vaccine is widely administered to reduce the risk of severe tuberculosis disease in children. Recent global vaccine supply issues have led to the use of alternative products, which may vary in side effect profile. We report on the safety of the Polish (Moreau strain) {"}Bacille Calmete-Guerin-10{"} vaccine in an Australian cohort. Using active surveillance, we identified an adverse event rate of 54.6 per 10,000 doses (95\% confidence interval: 38.5-75.2), which was comparable to that reported with the Danish Sanofi-Pasteur and Connaught strains.",

keywords = "adverse events following immunization, Bacille Calmete-Guerin, vaccine safety",

author = "Wong, \{Nicole X.\} and Jim Buttery and Alissa McMinn and Zainul Azhar and Crawford, \{Nigel W.\}",

year = "2020",

month = jun,

doi = "10.1097/INF.0000000000002630",

language = "English",

volume = "39",

pages = "E66--E68",

journal = "The Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams \& Wilkins",

number = "6",

}

TY - JOUR

T1 - Safety of the Polish BCG-10 Vaccine during a Period of BCG Vaccine Shortage

T2 - An Australian Experience

AU - Wong, Nicole X.

AU - Buttery, Jim

AU - McMinn, Alissa

AU - Azhar, Zainul

AU - Crawford, Nigel W.

PY - 2020/6

Y1 - 2020/6

N2 - Bacille Calmete-Guerin vaccine is widely administered to reduce the risk of severe tuberculosis disease in children. Recent global vaccine supply issues have led to the use of alternative products, which may vary in side effect profile. We report on the safety of the Polish (Moreau strain) "Bacille Calmete-Guerin-10" vaccine in an Australian cohort. Using active surveillance, we identified an adverse event rate of 54.6 per 10,000 doses (95% confidence interval: 38.5-75.2), which was comparable to that reported with the Danish Sanofi-Pasteur and Connaught strains.

AB - Bacille Calmete-Guerin vaccine is widely administered to reduce the risk of severe tuberculosis disease in children. Recent global vaccine supply issues have led to the use of alternative products, which may vary in side effect profile. We report on the safety of the Polish (Moreau strain) "Bacille Calmete-Guerin-10" vaccine in an Australian cohort. Using active surveillance, we identified an adverse event rate of 54.6 per 10,000 doses (95% confidence interval: 38.5-75.2), which was comparable to that reported with the Danish Sanofi-Pasteur and Connaught strains.

KW - adverse events following immunization

KW - Bacille Calmete-Guerin

KW - vaccine safety

UR - https://www.scopus.com/pages/publications/85084694950

U2 - 10.1097/INF.0000000000002630

DO - 10.1097/INF.0000000000002630

M3 - Article

C2 - 32150004

AN - SCOPUS:85084694950

SN - 0891-3668

VL - 39

SP - E66-E68

JO - The Pediatric Infectious Disease Journal

JF - The Pediatric Infectious Disease Journal

IS - 6

ER -

Safety of the Polish BCG-10 Vaccine during a Period of BCG Vaccine Shortage: An Australian Experience

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Cite this